Get started
Author

Anna Marie Juanitez

Observed names: A. M. Juanitez, A.M. Juanitez, Anna Juanitez, Anna M Juanitez, Anna M. Juanitez
OpenAlex ID: A5048781505
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024 · Christopher Melani, Rahul Lakhotia, et al. · New England Journal of Medicine · 75
PDF
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
2020 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 17
Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2023 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 6
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
2022 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 6
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
2024 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 4
PDF
Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
2019 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 4
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
2022 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 3
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis
2021 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 3
45 | MULTI‐TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)
2025 · C. Melani, R. Lakhotia, et al. · Hematological Oncology · 2
PDF
PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B‐CELL LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS
2019 · C.J. Melani, R. Lakhotia, et al. · Hematological Oncology · 2
Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma
2025 · Max J. Gordon, Rahul Lakhotia, et al. · British Journal of Haematology · 1
PDF
316 | Multi‐targeted Therapy With Vipor‐p in Relapsed/refractory Diffuse Large B‐cell Lymphoma: Updated Analysis of Efficacy and Minimal Residual Disease
2025 · C. Melani, R. Lakhotia, et al. · Hematological Oncology · 1
PDF
Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
2024 · Christopher Melani, Rahul Lakhotia, et al. · Blood · 1
Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies
2024 · Christopher Melani, Max Gordon, et al. · Blood Cancer Discovery · 1
POSTER: MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
2023 · Rahul Lakhotia, Stefania Pittaluga, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)
2023 · C. J. Melani, R. Lakhotia, et al. · Hematological Oncology · 1
PDF
Abstract A027: Combination targeted therapy with ViPOR in relapsed/refractory (R/R) and treatment-naïve (TN) mantle cell lymphoma (MCL): Analysis of safety, efficacy, and minimal residual disease (MRD)
2026 · Christopher Melani, Rahul Lakhotia, et al. · Blood Cancer Discovery
MCL-349 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
2023 · Rahul Lakhotia, Stefania Pittaluga, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 18
Citation count: 128
H-index: 4
I10-index: 2
Year
Topic
Type